HIV蛋白酶抑制剂依地那韦药效学、药动学及治疗艾滋病的临床应用

Study on pharmacodynamics and pharmacokinetics of HIV protease inhibitor Indinavir and its treatment for AIDS

目的:介绍蛋白酶抑制剂依地那韦治疗艾滋病.方法:采用国际多中心、随机、双盲等方法,三联疗法:一个蛋白酶抑制剂加二个核苷类逆转录酶抑制剂与二联疗法,单一蛋白酶抑制剂作疗效比较.结果:采用包括依地那韦在内的三联疗法在提高CD_4细胞计数,降低HIV病毒负荷疗效最好.三联疗法组比二联疗法组死亡几乎减少一半.结论:以蛋白酶抑制剂如依地那韦为主的三联疗法可提高CD_4细胞计数,HIV病毒负荷降到检测水平以下,从而提高了存活率,降低了死亡率.

OBJECTIVE: To recommend the protease inhibitors Indinavir for AIDS treatment. METHODS: Adopt international multicentral randomized double blind method. 3 drug group: 1 protease inhibitor plus 2 nucleoside derivative reverse transcriptase inhibitors and 2 drugs group and pure protease inhibitor as efficacy contrast. RESULTS: Cocktail therapy including the indinavir have a best results, can rise their CD4 cell counts and lower plasma HIV viral load. Compared with the two - drugs group, mortality rate of the three - drug group decreased by half. CONCLUSION: Cocktail therapy Including the indinavir can be rise the survival rate and decreased the mortality rate.